TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Dasatinib With Fludarabine and Rituximab in Relapsed and Refractory CLL and SLL

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* CLL/SLL with cells positive by flow cytometry (or immunostaining) for CD19, CD23, and CD5. Patients may be CD23 negative as long as they are also cyclin D1 negative or t(11;14) negative.~* Participants must have received at least 1 prior regimen containing a purine analogue or have received at least 2 chemotherapy regimens not containing a purine analogue. Patients may be refractory to single-agent purine analogue treatment, but patients may not be refractory to a combination of purine analogue with rituximab. Patients may have received rituximab.~* 18 years of age or older~* Able to take oral medications~* ECOG Performance Status of 2 or better~* Adequate organ function to tolerate chemotherapy~* Women of childbearing potential must have a negative serum or urine pregnancy test within 72 hours prior to the start of study drug administration and agree to use and utilize an adequate method of contraception throughout treatment and for at least 4 weeks after study is stopped.~* Require treatment based on 1996 NCI-WG criteria updated in 2008 by the IWCLL~* Patient agrees to discontinue St. John's Wort while receiving dasatinib therapy and stop at least 5 days before starting dasatinib.~* Patient agrees that IV bisphosphonates will be withheld for the first 8 weeks of dasatinib~Exclusion Criteria:~* Pregnant or breastfeeding women~* Uncontrolled angina, congestive heart failure, or MI within 6 months~* Diagnosed or suspected congenital long QT syndrome~* Any history of clinically significant ventricular arrhythmias~* Prolonged QTc interval on pre-entry ECG~* Uncontrolled hypertension~* Hypokalemia or hypomagnesemia that is not corrected prior to dasatinib administration~* Patients should not be taking drugs that are generally accepted to have a risk of causing Torsades de Pointes~* Known HIV positive~* Known significant bleeding disorder unrelated to CLL~* Any significant pleural or pericardial effusion~* Patients may not have another malignancy that is uncontrolled or requires treatment within a year of starting this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- dasatinib, rituximab, fludarabine (Type: OTHER): Single-arm, open-label

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study of LY3454738 in Adults With Chronic Spontaneous Urticaria

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Must agree to use appropriate birth control throughout the study~* Must have a diagnosis of CSU for at least 6 months~* Must have CSU symptoms for at least 8 consecutive weeks despite taking anti-histamines~* Must agree to take an anti-histamine every day during the trial~* Must be willing to enter information about symptoms in an electronic diary twice a day~Exclusion Criteria:~* Must not have a cause, other than CSU, for itching, hives, and/or angioedema (swelling beneath the skin)~* Must not have a current or recent active infection requiring antibiotics~* Must not have a history of anaphylaxis (severe, life threatening allergic reaction)~* Must not have asthma requiring medications other than short acting beta agonists (albuterol, etc.)~* Must not have received prior treatment with omalizumab, ligelizumab, or other experimental biologic for CSU

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- LY3454738 (Type: EXPERIMENTAL): 500 milligram (mg) LY3454738 administered intravenously (IV).
- Placebo (Type: PLACEBO_COMPARATOR): Placebo administered IV.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Optical Coherence Tomography: An Adjunct to Flexible Bronchoscopy in the Diagnosis of Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subjects 18-99 years of age~* Presence of an endobronchial mass~* Need for flexible bronchoscopy, with endobronchial biopsies~Exclusion Criteria:~* PCO2 \> 47 mm Hg, and/or long term Oxygen therapy~* Unwillingness to undergo fiberoptic bronchoscopy~* Coagulopathy, defined as a platelets count \< 100.000/mm3, or an INR\> 1.4, or known clinical bleeding disorder~* Therapy with anticoagulant, including Coumadin and Clopidogrel~* Renal dysfunction, defined as a Creatinine \> 2 mg/dl~* Life-threatening arrhythmias, or history of myocardial infarction within 6 months~* Cerebrovascular Accident within the preceding 6 months~* Facial abnormality preventing safe introduction of the bronchoscope~* Uncontrolled hypertension~* Active liver disease~* Pregnancy or Breastfeeding~* Prisoners~* Inability to give informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Optical Coherence Tomography (Type: None): Examine OCT images and compare them to conventional biopsies in same subject.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Pemetrexed, Gemcitabine, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically confirmed carcinoma arising from the pancreas~  * Stage II or III disease, meeting 1 of the following criteria:~    * Nonresectable disease~   * Potentially resectable disease~   * Resectable disease~ * Stage IV disease with symptomatic back pain requiring palliation allowed at the discretion of the principal investigator~* Measurable, evaluable, or nonmeasurable disease~* No neuroendocrine tumor of the pancreas~* No documented brain metastasis~* No clinically significant pleural or peritoneal effusions that cannot be drained~PATIENT CHARACTERISTICS:~* ECOG performance status 0-1~* Life expectancy ≥ 12 weeks~* Absolute neutrophil count ≥ 1,500/mm³~* Platelet count ≥ 100,000/mm³~* Hemoglobin ≥ 9 g/dL~* Serum bilirubin ≤ 1.5 times upper limit of normal (ULN)~* Alkaline phosphatase ≤ 3 times ULN (5 times ULN if liver has tumor involvement)~* AST and ALT ≤ 3 times ULN (5 times ULN if liver has tumor involvement)~* Creatinine clearance ≥ 45 mL/min~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception during and for 3 months after completion of study treatment~* No active infection~* No serious systemic disorders that would preclude study treatment~* No significant cardiovascular disease in the form of abnormal electrocardiogram coupled with clinical features of recent or recurrent cardiac disease (including myocardial infarction, angina, or hypertension)~PRIOR CONCURRENT THERAPY:~* More than 4 weeks since prior investigational agents~* No prior chemotherapy for pancreatic cancer~* Must be able to discontinue aspirin, dexamethasone, and other nonsteroidal anti-inflammatory agents for 2 days before, the day of, and 2 days after pemetrexed disodium dose (5 days before for long-acting agents such as piroxicam)~* Must be able and willing to take folic acid and cyanocobalamin (vitamin B12) supplementation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Pemetrexed in combination with concomitant radiotherapy (Type: EXPERIMENTAL): Patients will receive Pemetrexed plus Radiotherapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of DERMABOND ProPen in Closure of Colectomy Wounds

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients undergoing elective colectomies for benign or malignant conditions~* Midline vertical incisions or skin crease incisions~* Above the age of 21 years old~* Able to make own valid informed decisions~Exclusion Criteria:~* Patients undergoing surgery for recurrent or metastatic disease~* Surgery for surgical emergencies such as acute abdomen or bleeding~* Known allergy to DERMABOND ProPen Tissue Adhesive or any of its constituents (cyanoacrylate or formaldehyde)~* Patients on immunosuppression

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Skin Staples (Type: ACTIVE_COMPARATOR): Skin closure with skin staples
- Dermabond (Type: EXPERIMENTAL): Closure of abdominal wound with dermabond (2-octylcyanoacrylate)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of TOBI Podhaler vs. Tobramycin Inhalation Solution

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Adult (≥ 18 years) diagnosed with cystic fibrosis~2. Airway colonization with Pseudomonas aeruginosa that is sensitive to tobramycin in vitro and currently managed with Tobramycin inhaled solution who are interested in switching to the TOBI Podhaler.~Exclusion Criteria:~1. Persons unable to communicate in English,~2. Pregnant patients,~3. Patients \< 18 years of age

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Adults- Cystic Fibrosis (Type: None): Adults with cystic fibrosis who have respiratory colonization with Pseudomonas Aeruginosa. The actual study will involve instructing adult patients with CF on the use of a new form of Tobramycin for inhalation (powder) and then assessing this new form of TOBI podhaler vs the old TOBI solution related to patient preference on use, time involved in taking the new medication vs the old, and impact on their pulmonary function and subsequent exacerbation rate plus quality of life.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess Safety, Tolerability and Pharmacokinetics of of AZD6553 in Healthy Volunteers and Patients With Chronic Obstructive Pulmonary Disease (COPD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Parts A and B only; Body mass index (BMI) between 18 and 30 kg/m2.~* Parts A and B only; Normal physical examination, laboratory values, and vital signs (blood pressure and pulse) unless the investigator considers an abnormality to be clinically irrelevant.~* Part C only; clinical diagnosis of COPD for at least one year and Post-bronchodilator FEV1 30 - 80% predicted, FEV1/FVC ratio \< 70%~Exclusion Criteria:~* Participation in any clinical study with an investigational drug or new formulation of a marketed drug in the 3 months prior to Visit 2, or participation in a method development study one month prior to Visit 1~* Part C only: An acute exacerbation or acute respiratory infection (upper or lower) in the 4 weeks prior to Visit 1 or Visit 2.~* Part C only: Concomitant diagnosis of significant pulmonary disease other than COPD, including symptomatic asthma, cystic fibrosis and allergic bronchopulmonary aspergillosis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Can Ultrasound be Used to Verify CVC Position and to Exclude Pneumothorax?

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female 18 years or older~* Signed consent~* In need of subclavian or internal jugular central line placement~Exclusion Criteria:~* Any subject who refuses or whose family refuses to sign consent~* Any subject in whose immediate transfer from the care of the ED to another location is mandated by clinical presentation~* Any subject under the age of 18~* Any subject being evaluated for chest trauma.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CVC Internal Jugular or Subclavian Vein (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Patient Satisfaction With Virtual Visits

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria~* Age greater than 18~* Able to provide informed consent without assistance~* English speaking~* Access to phone or device equipped for virtual visit~Exclusion criteria~* Surgeon determines participant is not a good candidate for virtual follow-up visit~* Suspicion of malignancy~* Unable to provide informed consent~* No access to technology for virtual visit

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Virtual visit (Type: EXPERIMENTAL): Patients will have 2-week post-operative virtual visit
- Office visit (Type: ACTIVE_COMPARATOR): Patients will return to the office for a 2-week post-operative visit

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Prospective Study to Evaluate Outcomes From Transoral BOT Resection for OSAHS

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Any patient with documented OSAHS who is scheduled for tongue base resection at UAB~2. Age \> 18~3. Patients must sign informed consent~Exclusion Criteria:~1. Psychological condition that renders the patient unable to understand the informed consent~2. Any situation or condition that will interfere with adherence to study activities

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Combination Chemotherapy and Tipifarnib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically confirmed acute myeloid leukemia (AML) according to the WHO classification system~  * High-risk disease~ * Newly diagnosed disease~ * Patients with secondary AML due to prior chemotherapy for a different malignancy are eligible~* No known inv(16), t(8;21), or t(15;17) cytogenetic abnormality~* No acute promyelocytic leukemia~* No CNS leukemia~PATIENT CHARACTERISTICS:~Age~* 18 to 59~Performance status~* ECOG 0-2~Life expectancy~* More than 6 months~Hematopoietic~* Not specified~Hepatic~* AST and ALT ≤ 2.5 times upper limit of normal~* Bilirubin normal~Renal~* Creatinine normal OR~* Creatinine clearance ≥ 60 mL/min~Cardiovascular~* Ejection fraction \> 50% by echocardiogram or MUGA~* No symptomatic congestive heart failure~* No unstable angina pectoris~* No cardiac arrhythmia~Immunologic~* No known HIV positivity~* No history of allergic reactions attributed to compounds of similar chemical or biological composition to tipifarnib~* No allergy to imidazoles (e.g., clotrimazole, ketoconazole, miconazole, or econazole)~* No ongoing or active infection~Other~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* No other uncontrolled illness~* No psychiatric illness or social situation that would preclude study compliance~PRIOR CONCURRENT THERAPY:~Biologic therapy~* No concurrent epoetin alfa~Chemotherapy~* See Disease Characteristics~* No prior chemotherapy for AML or myelodysplastic syndromes except hydroxyurea~Endocrine therapy~* Not specified~Radiotherapy~* No concurrent palliative radiotherapy~Surgery~* Not specified~Other~* More than 30 days since prior investigational agents~* No other concurrent investigational or commercial agents or therapies for the malignancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 59 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: CoQ10 and Prednisone in Non-Ambulatory DMD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Age 10-18 years~* Non-ambulatory (primary mode of transportation is via wheelchair for 3 years or less)~* Confirmed DMD diagnosis~* Steroid-naive for the 6 months prior to screening~* Stable dose of b-blocker or ACE inhibitor medication for the 6 months prior to screening, if taking either of these medications~* Ability to provide reproducible repeat QMT grip score within 15% of first assessment score~* Has not participated in other therapeutic research protocol within the last 6 months prior to screening~* Ability to swallow tablets~Exclusion Criteria:~* Failure to achieve one or more of the diagnostic inclusion criteria cited above~* Symptomatic DMD carrier~* Use of carnitine, other amino acids, creatine, glutamine, CoQ10 or any herbal medicines (this would not include herbal teas unless they are consumed daily with intended medicinal effect) within the last 3 months~* History of significant concomitant illness or significant impairment of renal or hepatic function, or other contraindication to steroid therapy~* Positive PPD~* No prior exposure to chickenpox and no immunization against chicken pox~* Baseline serum CoQ10 level of 5.0mg/ml or greater

- Gender: MALE
- Minimum Age: 10 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): CoenzymeQ10 taken once a day each morning by mouth.
- 2 (Type: ACTIVE_COMPARATOR): Prednisone taken once a day each morning by mouth
- 3 (Type: ACTIVE_COMPARATOR): CoenzymeQ10 and prednisone each taken once a day in the morning by mouth.
- 4 (Type: NO_INTERVENTION): Enhanced standard of care.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Outpatient Foley Catheter for Induction of Labor in Nulliparous for Prolonged Pregnancy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* prolonged pregnancy (D+4) nulliparous no complication during pregnancy location near th hospital (20 mn by car) Bishop \< 6~Exclusion Criteria:~* medical history small for gestationnal age PROM Live alone

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Foley catheter (Type: ACTIVE_COMPARATOR): The patient will have an induction at home after 60 mn of fetal heart rate monitoring.
- Expectative (Type: SHAM_COMPARATOR): The patient in this arm will have the actual care (expectative until the next day befor starting the induction)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Relationship of Hemoglobin A1c and Diabetic Wound Healing

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* \>18 years of age~* Diabetic (Type I and Type II)~* Ulceration of the foot at least one centimeter in width/length~* Ulceration at least 0.2 centimeters in depth~Exclusion Criteria:~* Ulceration width/length \> 7.5 centimeters~* Wound depth \> 1.25 centimeters~* Purulent, excessive drainage and/or other signs of infection (i.e. erythema, edema, warmth)~* Inability to provide informed consent~* Inability to swallow pills (vitamin C supplement)~* Patients with concurrent renal problems~* Patients with medication contraindications to Vitamin C and/or topical wound dressings

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bacitracin wound care dressing alone (Type: ACTIVE_COMPARATOR): Bacitracin wound care dressing alone
- Bacitracin with Vit C (Type: ACTIVE_COMPARATOR): Bacitracin wound care dressing with Vitamin C supplementation
- AmeriGel® wound care dressing alone (Type: ACTIVE_COMPARATOR): AmeriGel® wound care dressing alone
- AmeriGel® with Vit C (Type: ACTIVE_COMPARATOR): AmeriGel® wound care dressing with Vitamin C supplementation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues